GlaxoSmithKline Pakistan Ltd
Shariah compliantAlphaGen's view
Members only- Alpha scoreHow this quarter's business compares, scored 0–100
- Fair valueWhat the stock may be worth, against today's price
- Trend signalWhether the price trend is up, down or stopping
- Sector rankWhere it stands among its sector peers
Latest results
Quarter: Apr–Jun 2026In the Apr–Jun 2026 quarter, GLAXO's sales fell 2% to Rs 14.5bn, from Rs 14.7bn, and profit after tax fell 5% to Rs 2.0bn, from Rs 2.1bn (compared with Apr–Jun 2025).
Earnings per share were Rs 6.19, against Rs 6.50 a year earlier. The company reported a dividend of Rs 7.00 per share for the quarter.
At Rs 307.82, GLAXO trades at 10.4 times earnings, with a dividend yield of 5.0%.
- P/E ratio
- 10.4
- Dividend yield
- 5.0%
- Dividend payout
- 113%
- of earnings
- Return on equity
- 30%
- Net margin
- 16.0%
- trailing twelve months
- Debt to equity
- 0.01
GLAXO quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Apr–Jun 2026 | Rs 14.5bn | Rs 2.0bn | 13.6% | Rs 6.19 | Rs 7.00 |
| Jan–Mar 2026 | Rs 17.0bn | Rs 2.6bn | 15.3% | Rs 8.20 | — |
| Oct–Dec 2025 | Rs 21.4bn | Rs 3.8bn | 17.7% | Rs 11.90 | Rs 12.00 |
| Jul–Sep 2025 | Rs 14.2bn | Rs 2.0bn | 14.4% | Rs 6.40 | — |
| Apr–Jun 2025 | Rs 14.7bn | Rs 2.1bn | 14.1% | Rs 6.50 | Rs 5.00 |
| Jan–Mar 2025 | Rs 15.6bn | Rs 2.1bn | 13.7% | Rs 6.68 | — |
| Oct–Dec 2024 | Rs 17.6bn | Rs 3.0bn | 16.8% | Rs 9.27 | Rs 10.00 |
| Jul–Sep 2024 | Rs 14.7bn | Rs 1.9bn | 13.1% | Rs 6.05 | — |
GLAXO annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Dec 2025 | Rs 65.9bn | Rs 10.0bn | Rs 31.48 | Rs 17.00 |
| Year to Dec 2024 | Rs 61.2bn | Rs 6.5bn | Rs 20.52 | Rs 10.00 |
| Year to Dec 2023 | Rs 49.7bn | Rs 534.0mn | Rs 1.68 | — |
| Year to Dec 2022 | Rs 41.8bn | Rs 2.5bn | Rs 7.73 | — |
| Year to Dec 2021 | Rs 36.7bn | Rs 5.4bn | Rs 16.81 | Rs 7.00 |
Balance sheet and price
Balance sheet as of Jun 2026- Total assets
- Rs 52.6bn
- Shareholders' equity
- Rs 34.4bn
- Cash & bank
- Rs 8.4bn
- Total debt
- Rs 353.0mn
- Current ratio
- 2.28
- 3-month high
- Rs 387.01
- 3-month low
- Rs 300.07
- 1-month change
- -4.7%
- 3-month change
- -20.3%
Read more about GLAXO
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 927.73P/E 11.1
- AGPAGP LtdRs 157.87P/E 12.7
- BFBIOBF Biosciences LtdRs 127.51P/E 20.0
- CPHLCiti Pharma LtdRs 71.86P/E 15.7
- FEROZFerozsons Laboratories LtdRs 325.07P/E 16.4
- HALEONHaleon Pakistan LtdRs 680.74P/E 12.7
- HINOONHighnoon Laboratories LtdRs 948.13P/E 12.1
- HPLHoehcst Pakistan LtdRs 3905.85P/E 10.4
- IBLHLIBL HealthCare LtdRs 42.52P/E 19.1
- LIVENLiven Pharma LimitedRs 31.14
- MACTERMacter International LtdRs 259.64P/E 15.3
- OTSUOtsuka Pakistan LtdRs 366.30P/E 14.4
GLAXO: common questions
What is GLAXO's share price?
GlaxoSmithKline Pakistan Ltd (GLAXO) last closed at Rs 307.82 on the Pakistan Stock Exchange.
Does GLAXO pay a dividend?
Yes. GlaxoSmithKline Pakistan Ltd paid Rs 17.00 per share for the year to Dec 2025, and the stock's dividend yield is 5.0%.
What were GLAXO's latest results?
In the Apr–Jun 2026 quarter, GLAXO's sales fell 2% to Rs 14.5bn, from Rs 14.7bn, and profit after tax fell 5% to Rs 2.0bn, from Rs 2.1bn (compared with Apr–Jun 2025).
What is GLAXO's P/E ratio?
At Rs 307.82, GLAXO trades at 10.4 times its earnings.
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.